The stock is currently trading for $1.27 and has more than 4,700 trades in pre-market activity this morning. Closing in on a million shares of volume. Recent news said the phase 2 trial showed product efficacy
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
– Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer –
– Secondary endpoints including clinical benefit rate at 24 weeks and median progression-free survival were 40 percent and 2.6 months, respectively –
– Arm B did not pass protocol-defined futility boundary in triple-negative breast cancer; enrollment to Arms B and C to be discontinued –
– Company to host conference call and webcast today at 5:00 pm ET / 2:00 pm PT –
SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A) met its primary efficacy endpoint of confirmed objective response rate (ORR) of greater than 10 percent by central radiology review. Praluzatamab ravtansine is a DM4-conjugated, conditionally activated antibody-drug conjugate (ADC) targeting CD166 and is wholly owned by CytomX.
